In the past six months, Vir Biotechnology's stock has experienced several notable events, including a 19.02% increase in the six months leading up to September 3, 2025, and a 93.71% increase over the past year. On October 9, 2026, the stock price increased by 6.1% during mid-day trading, reaching $11.8030, and hit a 52-week high of $11.96. On October 8, 2026, VIR-5500, the company's prostate cancer candidate, received FDA Fast Track designation, which can accelerate its development and review process. On October 7, 2026, Vir appointed David Liu as its new Chief Medical Officer. The company is scheduled to present expanded Phase 2 SOLSTICE results for its hepatitis delta program at AASLD's The Liver Meeting® 2026. In its second quarter 2026 financial results reported on August 5, 2026, Vir announced a net income of $80.1 million, a significant improvement from the previous year, largely due to a substantial collaboration payment from Astellas, and reported over $1 billion in cash, cash equivalents, and investments. Phase 2 SOLSTICE data, presented at the EASL Congress, showed that the elebsiran and tobevibart combination achieved undetectable HDV RNA in 88% of chronic hepatitis delta participants at Week 96. Analyst ratings have been mixed but generally positive, with H.C. Wainwright reiterating a 'Buy' rating and raising its price target to $22, and Raymond James reiterating a 'Strong Buy' with a $19 price target, though Zacks Research downgraded the stock to 'Strong Sell'. The stock has exhibited volatile price movements, with a beta of 1.59.
